Opinion|Videos|December 10, 2024
Antibody Screening Tests for T1D
Panelists discuss how antibody screening tests for type 1 diabetes (T1D), including tests for insulin autoantibodies (IAA), glutamic acid decarboxylase (GAD) antibodies, and other markers can help identify individuals at risk for developing the disease before clinical symptoms appear, enabling earlier monitoring and potential intervention.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.
Tirzepatide gained an FDA cardiovascular indication after SURPASS-CVOT showed noninferiority to dulaglutide in high-risk adults.
FDA authorized Abbott’s Libre Duo 10 Day system, the first wearable device to continuously monitor both glucose and ketones.
Advertisement
Advertisement
Trending on Patient Care Online
1
Stroke Incidence Nearly Doubled Among Adults Younger Than 55 Over 3 Decades
2
GLP-1 RAs for Weight Management: A Primary Care Approach to Risk and Monitoring
3
FDA Approves Insulin Efsitora Alfa-Gobe for Adults With Type 2 Diabetes
4
FDA Approves Sotatercept-csrk Label Update for Newly Diagnosed PAH
5